1. Home
  2. Live Updates
  3. School of medicine communications department

Live Breaking News & Updates on School Of Medicine Communications Department

Stay updated with breaking news from School of medicine communications department. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BetterLife Enrolls First Patient in Interferon alpha-2b

BetterLife Enrolls First Patient in Interferon alpha-2b
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , British Columbia , Ahmad Doroudian , Betterlife Pharma , Altum Pharmaceuticals Inc , University Health Network , Michener Institute Of Education , Betterlife Pharma Inc , School Of Medicine Communications Department , University Of Toronto , Princess Margaret Cancer Centre , Toronto Rehabilitation Institute , Qlife Pharma , Altum Pharmaceuticals , Pontificia Universidad Cat , About Betterlife , Latin America , Times Higher Education , Universidad Cat , Health Network , Toronto General , Toronto Western Hospitals , Michener Institute , Chief Executive Officer , Jamie Hooper ,

BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003 Trial to be Conducted by Pontificia Universidad Católica de Chile in Q2 2021


NPAU), today announced that its wholly-owned subsidiary, Altum Pharmaceuticals (“Altum”) has entered into a Letter of Intent with Pontificia Universidad Católica de Chile to conduct a randomized placebo-controlled trial (“IN2COVID”) in COVID-19 patients testing Altum’s proprietary inhaled interferon alpha-2b product, AP-003. The trial is projected to start in Q2 of this year and be completed by end of Q3.
Interferon alpha-2b (“IFN-a2b”), a Type I interferon, is a naturally occurring protein integral to the body’s first line of anti-viral defenses. There is evidence that coronaviruses, such as SARS-CoV-2, have mechanisms which suppress IFN-a2b production, allowing the virus to evade the innate immune system. Multiple clinical analyses show a significant link between deficiency in Type 1 interferon and development of severe COVID-19 disease. There is also accumulating evidence from preclinical studies that coronavirus replication is blo ....

United States , British Columbia , Ahmad Doroudian , Camila Diaz , Betterlife Pharma , School Of Medicine Communications Department , Altum Pharmaceuticals Inc , Our University , Betterlife Pharma Inc , Altum Pharmaceuticals , Pontificia Universidad Cat , About Betterlife Pharma , Qlife Pharma , Latin America , Times Higher Education , Universidad Cat , Chief Executive Officer , Medicine Communications , ஒன்றுபட்டது மாநிலங்களில் , பிரிட்டிஷ் கொலம்பியா , கமிலா டியாஸ் , பள்ளி ஆஃப் மருந்து தகவல்தொடர்புகள் துறை , ஆடும் மருந்துகள் இன்க் , அவர் பல்கலைக்கழகம் , ஆடும் மருந்துகள் , வாழ்க்கை பார்மா ,